A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846
Healthy man aged between 19 to 55 at screening
Weight ≥ 55kg
Body mass index (BMI) of 18.5 to 27.0kg/m2
Those who agree to contraception from the first Investigational Product(IP) dosing day till 6 months after the last dosing day and decide not to provide sperm during the participation of clinical trial
Those who have clinically significant disease or medical history of Hepatopathy, Renal, Neurological, Immunity, Respiratory, Endocrine, urinary, tumor or Psychical disorder
Those who have a history of clinically significant cardiovascular diseases such as myocardial infarction, angina pectoris, ventricular arrhythmia, heart failure, left ventricular outflow tract stenosis, stroke, and transient ischemic attack within 2 years prior to the first administration of the investigational drug
Those with eye diseases including genetic degenerative retinal diseases, including retinitis pigmentosa
Those with a past history of erection lasting more than 4 hours and priapism while taking PDE5 inhibitors such as tadalafil